Sugi Predict

Sugi Predict / Compounds / SCHEMBL578244

SCHEMBL578244

SCHEMBL578244

CN1CCC(O)(c2ccc(Br)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 3/20 0.55
▸ OPRK1 P41145 3/20 0.55
▸ OPRD1 P41143 2/20 0.55
▸ OPRL1 P41146 2/20 0.55
▸ DRD2 P14416 4/20 0.47
▸ DRD3 P35462 4/20 0.47
▸ NR1I2 O75469 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ HTR1A P08908 1/20 0.47
▸ ADRA2A P08913 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CHRM1 P11229 1/20 0.47
▸ ADRA2B P18089 1/20 0.47
▸ ADRA2C P18825 1/20 0.47
▸ CHRM3 P20309 1/20 0.47
▸ SLC6A2 P23975 1/20 0.47
▸ HTR2A P28223 1/20 0.47
▸ SLC6A4 P31645 1/20 0.47
▸ ADRA1A P35348 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10028305 0.90 OPRL1 (0.46) OPRM1OPRK1OPRD1OPRL1
SCHEMBL17888226 0.82 CYP2D6 (0.48) OPRM1OPRK1OPRD1OPRL1DRD2
SCHEMBL10424458 0.82 OPRM1 (0.57) OPRM1OPRK1OPRD1OPRL1DRD2
SCHEMBL16936710 0.81 OPRM1 (0.53) OPRM1OPRK1OPRD1OPRL1DRD2
SCHEMBL12526871 0.81 OPRM1 (0.53) OPRM1OPRK1OPRD1OPRL1DRD2
SCHEMBL15573716 0.81 OPRM1 (0.53) OPRM1OPRK1OPRD1OPRL1DRD2
SCHEMBL3591425 0.81 CCR3 (0.57) OPRM1OPRK1OPRD1OPRL1DRD2
SCHEMBL3785944 0.81 OPRM1 (0.55) OPRM1OPRK1OPRD1OPRL1DRD2
SCHEMBL1284894 0.81 ALDH1A1 (0.46) OPRM1OPRK1OPRD1OPRL1ADRA2C
SCHEMBL13189385 0.81 OPRL1 (0.41) OPRM1OPRK1OPRD1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132140-A1 IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS BENEVOLENTAI BIO LTD (GB) 2026-05-14 — — US disclosed
EP-4712969-A1 CYCLIN INHIBITORS Circle Pharma, Inc. (US) 2026-03-25 — — EP disclosed
EP-4590671-A1 IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS BenevolentAI Bio Limited (GB) 2025-07-30 — — EP disclosed
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 — — EP disclosed
US-20240408169-A1 CYCLIN INHIBITORS CIRCLE PHARMA, INC. 2024-12-12 — — US disclosed
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 — — US disclosed
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 — — US disclosed
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 — — US disclosed
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF LIFEARC (GB) 2024-06-27 — — US disclosed
WO-2024062250-A1 IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS BENEVOLENTAI BIO LIMITED (GB) 2024-03-28 — — WO disclosed
EP-2417127-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME University Health Network (CA) 2012-02-15 — — EP disclosed
CN-102341400-A Pyrrolopyrimidines useful as kinase inhibitors MEDICAL RES COUNCIL TECHNOLOGY 2012-02-01 — — CN disclosed
EP-2403853-A1 PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS Medical Research Council Technology (GB) 2012-01-11 — — EP disclosed
US-20110263598-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER UNIVERSITY HEALTH NETWORKS (CA) 2011-10-27 — — US disclosed
US-20110118230-A1 DIAZACARBAZOLES AND METHODS OF USE GENENTECH, INC. 2011-05-19 — — US disclosed
US-20110092501-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-04-21 — — US disclosed
US-20110092501-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-04-21 — — US disclosed
WO-2011029920-A1 HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2011-03-17 — — WO disclosed
WO-2010115279-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME UNIVERSITY HEALTH NETWORK (CA) 2010-10-14 — — WO disclosed
WO-2010100431-A1 PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-09-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132140-A1 IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS CHEK1, CHEK2, BUB1 OPRM1 2926/4885OPRK1 1362/4885OPRD1 2982/4885
US-20110118230-A1 DIAZACARBAZOLES AND METHODS OF USE CHEK1, CHEK2, BUB1B OPRM1 4879/4885OPRK1 4623/4885OPRD1 4836/4885
US-20110263598-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER MAP3K6, MAP3K5, MAP3K19 OPRM1 3567/4885OPRK1 1072/4885OPRD1 3941/4885
US-20110092501-A1 NOVEL INHIBITORS GLUL, QPCT, GLS OPRM1 3659/4885OPRK1 3019/4885OPRD1 2067/4885
US-20240408169-A1 CYCLIN INHIBITORS CCNI, CDK2, CDK1 OPRM1 4650/4885OPRK1 4148/4885OPRD1 4510/4885
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 OPRM1 3379/4885OPRK1 2106/4885OPRD1 3634/4885
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF WEE1, WEE2, DCLRE1B OPRM1 4811/4885OPRK1 4745/4885OPRD1 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.